The Antibiotic Resistance Crisis: How Emerging Pathogens are Influencing Empiric Therapy in the Febrile Neutropenia Market.
The Febrile Neutropenia (FN) Market is experiencing consistent and robust growth, primarily fueled by the increasing standardization of prophylaxis in high-risk cancer patients. Clinical guidelines from major oncology bodies (like ASCO and NCCN) strongly recommend the use of Granulocyte Colony-Stimulating Factors (G-CSFs) for patients whose chemotherapy regimen carries a high risk of FN. This...
0 Comments 0 Shares 503 Views 0 Reviews